The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - Boehringer Ingelheim; Debiopharm Group; Merck Sharp & Dohme; Nanobiotix; Pfizer
Research Funding - Bayer; Janssen; Novartis; Sanofi
 
Lisa Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI
 
Danny Rischin
Research Funding - Genentech/Roche; Merck; Threshold Pharmaceuticals
 
John Waldron
No Relationships to Disclose
 
Barbara Burtness
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Debiopharm Group; MedImmune; Merck; VentiRx
Research Funding - Merck
 
Vincent Gregoire
No Relationships to Disclose
 
Tulin Shekar
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Holly M. Brown
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jonathan D. Cheng
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Lillian L. Siu
Consulting or Advisory Role - Merck
Research Funding - Merck (Inst)